Federica Di Nicolantonio

Candiolo, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 110 publications

α-ketoglutarate/succinate ratio imbalance impairs thymine DNA glycosylase function and base excision repair process increasing susceptibility to pancreatic cancer.

α-ketoglutarate/succinate ratio imbalance impairs thymine DNA glycosylase function and base excision repair process increasing susceptibility to pancreatic cancer.

Journal: Cell death & disease
Published: September 04, 2025

Post-surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection.

Post-surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection.

Journal: International journal of cancer
Published: August 05, 2025

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC).

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC).

Journal: BMC cancer
Published: February 11, 2025

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers.

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers.

Journal: BJC reports
Published: February 08, 2025

A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection.

A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection.

Journal: Diagnostics (Basel, Switzerland)
Published: September 11, 2024

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition.

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition.

Journal: NPJ precision oncology
Published: March 04, 2024

Mutational signatures of colorectal cancers according to distinct computational workflows.

Mutational signatures of colorectal cancers according to distinct computational workflows.

Journal: Briefings in bioinformatics
Published: February 20, 2024

Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer.

Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer.

Journal: Molecular oncology
Published: January 25, 2024

Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer.

Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer.

Journal: EBioMedicine
Published: December 07, 2023

DNA demethylation triggers cell free DNA release in colorectal cancer cells.

DNA demethylation triggers cell free DNA release in colorectal cancer cells.

Journal: Genome medicine
Published: July 31, 2023

Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.

Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.

Journal: Molecular oncology
Published: July 27, 2023

Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models.

Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models.

Journal: Cancer cell
Published: April 25, 2023
Showing 1-12 of 110

Last Updated: 09/26/2026